Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abcellera Biologics Inc
(NQ:
ABCL
)
2.630
+0.020 (+0.77%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,536
Open
2.630
Bid (Size)
2.620 (10)
Ask (Size)
2.630 (21)
Prev. Close
2.610
Today's Range
2.630 - 2.649
52wk Range
2.400 - 6.055
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
August 20, 2024
Via
Benzinga
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...
Via
Talk Markets
Performance
YTD
-54.10%
-54.10%
1 Month
-19.33%
-19.33%
3 Month
-35.54%
-35.54%
6 Month
-46.87%
-46.87%
1 Year
-52.18%
-52.18%
More News
Read More
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
August 07, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AbCellera Reports Q2 2024 Business Results
August 06, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
July 31, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
Via
Talk Markets
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday
July 28, 2024
Via
Talk Markets
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
Via
The Motley Fool
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
Via
Talk Markets
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
July 02, 2024
Via
Talk Markets
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
June 25, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
Via
Talk Markets
Down 57%, Is AbCellera Biologics a Buy on the Dip?
June 13, 2024
Via
The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
June 10, 2024
Via
Talk Markets
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
May 28, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
Via
Talk Markets
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
May 20, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
3 Stock Gems Hiding in the Nasdaq
May 13, 2024
Via
InvestorPlace
5 Of 7 AI Categories Rose, Slightly,Over Past Week
May 11, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
May 08, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
AbCellera Reports Q1 2024 Business Results
May 07, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.